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Abstract
The complement system is an essential part of the innate immune system by acting as a first line of defense which is
stabilized by properdin, the sole known positive regulator of the alternative complement pathway. Dysregulation of
complement can promote a diversity of human inflammatory diseases which are treated by complement inhibitors. Here,
we generated a novel blocking monoclonal antibody (mAb) against properdin and devised a new diagnostic assay for this
important complement regulator. Mouse mAb 1340 specifically detected native properdin from human samples with high
avidity. MAb 1340 inhibited specifically the alternative complement mediated cell lysis within a concentration range of 1–
10 mg/mL. Thus, in vitro anti-properdin mAb 1340 was up to fifteen times more efficient in blocking the complement system
as compared to anti-C5 or anti-Ba antibodies. Computer-assisted modelling suggested a three-dimensional binding epitope
in a properdin-C3(H2O)-clusterin complex to be responsible for the inhibition. Recovery of properdin in a newly established
sandwich ELISA using mAb 1340 was determined at 80–125% for blood sample dilutions above 1:50. Reproducibility assays
showed a variation below 25% at dilutions less than 1:1,000. Systemic properdin concentrations of healthy controls and
patients with age-related macular degeneration or rheumatic diseases were all in the range of 13–30 mg/mL and did not
reveal significant differences. These initial results encourage further investigation into the functional role of properdin in the
development, progression and treatment of diseases related to the alternative complement pathway. Thus, mAb 1340
represents a potent properdin inhibitor suitable for further research to understand the exact mechanisms how properdin
activates the complement C3-convertase and to determine quantitative levels of properdin in biological samples.
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Introduction
The complement system serves as a bridge between the innate
and the adaptive immune system. More than 40 blood proteins
interact in cascades to eliminate blood and tissue infectious agents
by opsonization, anaphylatoxins and cell lysis. However, activated
complement is a double-edged sword, capable of protecting from
pathogens as well as causing self-tissue damage. Complement
dysregulation is caused by mutations in complement genes, the
presence of autoantibodies or large tissue damage [1,2]. There is
abundant evidence for complement activation in several autoim-
mune, eye and kidney diseases [1,3].
Disease-associated variants in several complement genes in
patients with age-related macular degeneration (AMD) or atypical
haemolytic-uraemic syndrome (aHUS) directed the attention of
therapeutic interventions to the alternative complement pathway
[4–6]. Spontaneous or surface-dependent hydrolysis of comple-
ment protein 3 (C3) to C3(H2O) specifically activates this pathway
in human blood. C3(H2O) binds complement factor B and
interacts with complement factor D to form a fluid phase C3-
convertase which cleaves C3 in C3a and C3b. C3b opsonizes
target surfaces and binds factor B, which is cleaved by factor D,
yielding Bb. Properdin stabilizes five to ten-fold both the fluid-
phase (C3(H2O)Bb) and surface-bound (C3bBb) C3-convertase of
the alternative pathway [7]. Complement factor H (CFH)
dissociates the C3-convertase and in combination with factor I
inactivates the C3b protein [7,8]. In a positive feedback loop, C3-
convertase cleaves C3 and an additional C3b molecule comple-
ments C3bBb to form the C5-convertase. C5 cleavage initiates the
terminal complement pathway and mediates inflammation as well
as the formation of a cell membrane attack [9].
Properdin, the only known positive regulator of the complement
system, escalates and initiates the alternative pathway [7,10]. It is
expressed in various cell types, mainly leukocytes, resulting in a
systemic serum concentration of 4–25 mg/mL [11,12]. The
glycoprotein with a molecular weight of about 50 kDa consists
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of seven thrombospondin type I repeats (TSR) [13,14]. Under
physiological conditions, humoral properdin exists as cyclic
dimers, trimers and tetramers in a fixed ratio of 26:54:20
(dimer:trimer:tetramer) [15]. Recently, structural studies of
properdin multimers showed four TSR subunits of two monomers
forming a vertex which interacts with the C3-convertases [16]. In
this complex, properdin TSR 4 and 5 interact with the C3a-chain
while the Ba and Bb subunits of factor B bind to properdin
[16,17]. Which properdin subunit interacts with Ba or Bb remains
unknown [16–19]. Stabilization of the convertases is opposed by
CFH-mediated dissociation of Bb although direct inhibitory
regulation of properdin by CFH is not known.
Mutations in negative regulators of the C3-convertase result in
pathogenic tissue damage [20–24] and several studies in mice
implicate properdin in the pathogenesis of complement-mediated
tissue injury [25]. Miwa et al. described an alternative pathway-
dependent pathology in a renal ischemia-reperfusion mouse model
which was significantly ameliorated by properdin depletion [26]. A
similar effect was reported in a mouse model for abdominal aortic
aneurysm, where aneurysm formation was controlled by autoan-
tibodies and properdin activity [27]. Additionally, properdin-
deficient mice also showed a reduced severity of tissue damage in
two different models of arthritis [28,29]. Antibody-mediated
inhibition of properdin in these animal models prevented or
ameliorated disease development. Disease associated complement
activation in humans showed complement consumption and can
results in decreased properdin concentrations [30]. Consistent
with the animal models, rheumatoid arthritis patients showed a
decreased properdin concentration in synovial fluid [31]. Auto-
antibodies and properdin are also involved in pathologies of
neuromyelitis optica, Scho¨nlein-Henoch syndrome and systemic
lupus erythematosus (SLE) where systemic properdin concentra-
tions are also decreased [32–34]. These studies indicate the
potential of properdin as a therapeutic target in complement-
mediated disorders.
Several complement antibody-therapeutics are currently under
development, but only Eculizumab (anti-C5) is approved to treat
alternative pathway-associated disorders, aHUS and paroxysmal
nocturnal hemoglobinuria (PNH) [35]. Clinical evaluation of
Eculizumab demonstrated an improvement for aHUS patients
and a favorable tolerability profile [36].
Regulators of complement activation can prevent or facilitate
formation of convertases. Supplements with soluble negative
complement regulators are in clinical phase I (complement
receptor 1) or preclinical studies (CFH constructs, protectin)
[35]. For the inhibition of properdin, a monoclonal anti-properdin
antibody was described in 2000 but no further preclinical or
clinical studies have been pursued [37]. The main concern in the
context of complement inhibition is the risk of increased
susceptibility to infection. However, if properdin is the target, this
issue can be circumvented with prophylactic vaccination against
Neisseria meningitides, the only known life-threatening infection in
properdin-deficient patients [38].
In this study, we generated a novel mouse anti-properdin
antibody and characterized its specificity and avidity to human
properdin. We demonstrated that our monoclonal antibody
inhibits complement activation and allows defining properdin
serum levels in patients with complement-mediated diseases. Thus,
mAb 1340 may provide a promising future complement thera-
peutic and analytical tool.
Materials and Methods
Patient samples and ethics statement
Human blood samples were taken after approval of the local
ethics committees (University Regensburg, references 12-101-0241
and 12-101-0074). All donors signed a written consent form.
Patients with age-related macular degeneration (AMD, n = 20)
were recruited at the University Regensburg. Patients with
systemic lupus erythematosus (SLE, n = 6), connective tissue
diseases (CTD, n = 10), polymyalgia rheumatica (PR, n = 31),
rheumatoid arthritis (RA, n = 38), spondyloarthritis (SPA, n = 40)
and systemic sclerosis (SSc, n = 16) were recruited at the Asklepios
Klinikum Bad Abbach. All samples of patients with rheumatic
diseases were obtained prior to initiation of corticosteroid or
immunosuppressive therapy. Healthy blood donors (controls,
n = 26) were randomly chosen students and staff members of the
University Regensburg.
All mice were handled according to the good animal practice in
science. This study was carried out in strict accordance with the
recommendations in the Guidelines for the Care and Use of
Laboratory Animals of the Federation of European Laboratory
Animal Science Associations. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the regional
agency for animal health Regierung der Oberpfalz, Veterina¨rwe-
sen (permit number: TV 54-2532.4-04/12). All immunizations
and bleedings were performed under inhalational anesthesia
(Isoflurane), and all efforts were made to minimize suffering.
Materials
Monoclonal anti-properdin antibodies (A233, A235), anti-C5
antibody (A217) and Anti-Ba (A225) were obtained from Quidel,
San Diego, USA. MAb anti-botulinum toxin (BoNT) was
generated previously [39]. Cell culture reagents were purchased
from Life technologies, Darmstadt, Germany. All chemicals
without separate reference were commercially available from
Sigma-Aldrich, Munich, Germany.
Generation of monoclonal antibodies
Mouse monoclonal antibodies against human properdin were
generated as previously described [39]. Briefly, six weeks-old
female Balb/c mice (Charles River Laboratories, Sulzfeld,
Germany) were immunized five times with 25 mg human, purified
properdin (Quidel, San Diego, USA). Antigens were applied
subcutaneously in complete Freund’s adjuvants for priming
immunization and incomplete Freund’s adjuvants for follow-up
immunizations. Spleen cells were isolated and fused with myeloma
cell line P3-X63-AG8.653 (American Type Culture Collection,
Manassas, USA) using a ratio of 2:1 with polyethylene glycol 1500
(Roche Diagnostics, Mannheim, Germany) according to standard
procedures [40]. Cells were cultivated on BALB/c thymocytes as
feeder cells in RPMI 1640 media, containing 20% fetal calf serum,
50 mM 2-mercaptoethanol, 50 U/mL recombinant murine inter-
leukin 6, 1% glutamine, 5.8 mM azaserine and 100 mM hypoxan-
thine. On day 10–20 post fusion, hybridoma supernatant was
tested for properdin-binding in an indirect enzyme-linked
immunoassay (ELISA). Positive hybridomas were isolated and
subcloned by limiting dilution. Stability and clonality of hybrid-
omas were tested by intracellular immunoglobulin staining and
flow cytometry analysis [40]. Monoclonal antibodies were purified
using HiTrap protein G HP affinity column (GE Healthcare Life
Science, Piscatawa, USA). Purity was checked by SDS-PAGE.
The concentration of purified antibodies was measured using a
NanoDrop 1,000 spectrometer. Isotype was determined using a
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mouse isotyping kit (AbD serotec, Kidlington, UK). Antibody
biotinylation was performed as described before [39].
Indirect ELISA for antibody binding
MaxiSorp plates (Nalgene Nunc, Penfield, USA) were coated
with 0.5–1 mg/mL antigen in PBS (overnight, 4uC). All incubation
steps were completed with three subsequent washing steps with
wash buffer (PBS, 0.1% Tween 20). After blocking with blocking
buffer (PBS, 0.1% Tween 20, 2% skimmed milk) antibodies
serially diluted in blocking buffer (1,000–0.1 ng/mL) were added
(1 h). Detection was performed with a peroxidase-conjugated anti-
mouse immunoglobulin G (IgG) antibody (Jackson ImmunoR-
esearch Laboratories, West Groove, USA) and 3,39,5,59-tetra-
methylbenzidine (TMB, Seramun, Wolzig, Germany). Signal was
determined at 450 nm.
cDNA cloning of mouse properdin
Total RNA was extracted from mouse liver (RNeasy MiniKit,
QIAGEN, Hamburg, Germany). Full-length murine properdin
(NM_008823.3, nt 71–1462) was amplified with oligonucleotide
primers 59-GAATTCATGCCTGCTGAAATGCAAGCC-3‘ and
5‘-CTCGAGGGGTTTCTTCTCTTCTGGGTCT-3‘. The
PCR product was cloned into expression vector pEXPR-IBA103
(IBA, Goettingen, Germany). Human embryonic kidney cells 293-
EBNA (HEK, Life Technologies, Carlsbad, CA, USA) were
transfected with TransIT-LT1 Transfection Reagent (Mirus,
Madison, WI, USA). The supernatant was purified using Gravity
flow Strep-Tactin Sepharose Column (IBA, Goettingen, Ger-
many). Expression and purity was confirmed by Western blot
(antibody: StrepMAB-Classic conjugated to horseradish peroxi-
dase, IBA, Goettingen, Germany) and SDS-PAGE.
Immunoprecipitaton of properdin
Tosylactivated dynabeads (Life Technologies, Carlsbad, USA,
5 mg) were conjugated to 100 mg mAb 1340 according to the
manufacture’s protocol. Pooled human Serum (NHS, 1.5 mL) was
incubated with mAb 1340-dynabeads (50 mL, 1 h). After washing
with wash buffer, proteins were eluted using non-reducing
Laemmli sample buffer and denaturation at 95uC (10 min) [41].
Protein gel analysis and Western blot analysis
After immunoprecipitation, eluted samples and purified proteins
were denatured (5–10 min, 95uC) and analyzed on a non-reducing
6–12% SDS-PAGE with subsequent Coomassie staining (detection
limit 1 mg) as described before [41]. Proteins were separated and
transferred on a polyvinylidene difluoride membrane applying the
semi-dry blotting method [42]. After blocking with blocking buffer
(PBS, 0.1% Tween 20, 2% skimmed milk), the membrane was
incubated with 1 mg/mL mAb 1340 (5 mL in blocking buffer,
1 h). The washed membrane was treated with a peroxidase
conjugated anti-mouse IgG antibody (in blocking buffer, 30 min).
After six washing steps with PBS, antibody binding was detected
using ECL solution (100 mM Tris/HCl pH 8.8, 1.3 mM luminol,
0.6 mM p-coumaric acid, 4.6 mM hydrogenperoxide) (detection
limit 10 ng).
LC-MS/MS analysis
Visible bands from Coomassie-stained gels were excised,
washed and tryptically digested as published previously [43].
Resulting peptides were used for nano-LC-MS/MS-analysis on a
TripleTOF 5600+ QTOF mass spectrometer equipped with an
Ultimate 3000 nano-HPLC with precolumn concentration (pre-
column: 100 mm I.D., 2 cm, Acclaim PepMap100, 5 mm (Dionex,
Idstein, Germany); HPLC column: 75 mm I.D., Acclaim Pep-
Map100, 3 mm; 300 nL/min (Dionex, Idstein, Germany)). Sam-
ples were separated using a 30 min binary gradient from 4–30% B
(solvent A: 0.1% formic acid; solvent B: 0.1% formic acid in
acetonitrile). The mass spectrometer repeatedly acquired a survey
scan and MS/MS spectra of the four most intensive ions for 0.2 s
each. Database searches were accomplished using the Mascot
algorithm (version 2.3) on the Uniprot-database (version 05/2013).
Lysis assays
Complement activity of the alternative pathway was measured
in a hemolysis assay with sheep erythrocytes [44,45]. We intended
to avoid false-negative results for antibody testing and used
erythrocytes which were more resistant to lysis by human serum
[46]. Antibodies were serially diluted in MgEGTA buffer (20 mM
HEPES, 144 mM NaCl, 10 mM EGTA, 7 mM MgCl2, pH 7.4)
and preincubated with 20% NHS in MgEGTA buffer (15 min,
37uC). Sheep red blood cells (16108) were treated with 20% NHS-
antibody mixtures in MgEGTA buffer for 30 min (37uC). Lysis
was determined at 414 nm.
Alternatively, blocking activity of mAb was tested in an
Escherichia coli (E. coli) lysis assay. MAb in different concentrations
were preincubated either with 40% NHS in MgEGTA buffer
(alternative pathway) or 20% NHS in PBS (classical pathway)
(30 min, 37uC). E. coli Stbl3 (Life Technologies, Carlsbad, CA,
USA) cultures with an optical density of 1 at 600 nm were added.
E. coli cells were incubated at 37uC and growth was determined
after 3 h at 600 nm.
Determination of antibody sequence
The cDNA of hybridoma cell line 1340 was synthetized using
the RNeasy Plus Mini Kit (Qiagen, Hamburg, Germany) and the
Cloned AMV First-Strand cDNA Synthesis Kit (Life technologies,
Darmstadt, Germany). In order to amplify the IgG variable region
of heavy and light chain, the Mouse IgG Library Primer set
(Progen, Heidelberg, Germany) was used according to the
manufacturer’s protocol. The purified PCR products were ligated
into a pGEM-T plasmid (Promega, Mannheim, Germany). After
heat shock-induced plasmid transfection into competent E. coli
DH5a (Life Technologies, Carlsbad, CA, USA) the plasmid was
amplified in an overnight culture and isolated using the
NucleoSpin Plasmid kit (Macherey-Nagel, Du¨ren, Germany).
For Sanger sequencing a reaction mix with M13 primer (Promega,
Mannheim, Germany) and the BigDye Terminator v3.1 cycle
sequencing kit (Life Technologies, Carlsbad, USA) were used.
Depletion of properdin from human blood sample
MAb 1340 was coupled to a HiTrap NHS-activated affinity
column (GE Healthcare Life Science, Piscatawa, USA) according
to the manufacturer’s instructions. Properdin was depleted from
human serum and plasma by recirculation 3 ml over the mAb
1340 column for 2 h. Through flow was tested in the reported
sandwich ELISA and Western blot for properdin concentration.
There was no properdin detectable.
Sandwich ELISA for properdin detection
For development and optimization of the properdin specific
sandwich ELISA we tested different antibodies (mAb 1340, mAb
149 (inhouse anti-properdin mAb), mAb A233, mAb A235, pAb
goat anti-properdin (Complement technologies, Tyler, USA)),
buffer (PBS, PBS/T, 1% BSA/PBS/T, Casein buffer, 2% skim
milk in PBS/T, MgEGTA buffer) and detection systems
(streptavidin-peroxidase and poly-horseradish peroxidase). The
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studies with human blood were done with the most reliable,
sensitive and practical assay of the pre-evaluation studies.
MaxiSorp plates were coated with 2 mg/mL mAb A235 in PBS
overnight at 4uC. After blocking with blocking buffer (1 h), plates
were washed and incubated with different samples (1 h): serial
dilutions of pooled human plasma (NHP) or NHS in PBS (1:10–
1:156,250), properdin (100 ng/mL) spiked into properdin-deplet-
ed NHS or NHP, different species sera (1:1,250), mouse properdin
(500 ng/mL), bovine serum albumin (500 ng/mL) and unknown
serum samples (1:700) in PBS. Subsequently, washing and
incubation with biotinylated mAb 1340 was performed (1 h).
SA-POD (Jackson ImmunoResearch Laboratories, West Groove,
USA) and TMB were used for signal development. Optical density
was measured at 450 nm. Six different NHP or NHS standard
curves on one day or on different days were performed for intra-
assay and inter-assay variation, respectively. Coefficient of
variation (CV) was calculated by means and standard deviations
of absorbance values at 450 nm.
Software
The structure of the variable region of mAb 1340 was modeled
on the VBASE2 server [47], the Rosetta online server [48] and
with the proABC method [49]. Complementarity-determining
regions (CDR) prediction was performed with abYsis, VBASE2,
Rosetta and IMGT methods [50]. Visualizations of structures
were done with UCSF Chimera [51]. Data analyses were
performed with GraphPad Prism (GraphPad Software, San Diego,
USA).
Results
Newly generated monoclonal anti-properdin antibody
binds human properdin with high avidity
Mice were immunized with purified human properdin for the
generation of specific and high-affinity antibodies. The selected
mouse showed a specific serum titer of 1:220,000 against the target
protein. Among 1,900 screened hybridoma clones, a stable cell line
#1340 secreted anti-properdin antibodies. The binding strengths
of different monoclonal antibodies were tested in an ELISA with
immobilized human properdin (Figure 1). MAb 1340, together
with two commercial anti-properdin mAb, i.e. mAb A233 and
A235 interacted concentration-dependent with the designated
antigen. We detected comparable avidities for mAb 1340, A233
and A235 with half maximal effective concentrations (EC50) of
0.16 nM, 0.07 nM and 0.1 nM, respectively. The described
antibodies showed similar binding strengths as an established
anti-complement mAb Eculizumab (anti-C5 mAb, 0.12 nM) and
even a higher mAb-antigen interaction as the routinely used
therapeutic mAb Bevacizumab (anti-VEGF, 0.8 nM) [52,53]. In
consideration of a broad affinity range from 1 pM to 1 nM of
therapeutic antibodies the newly described mAb 1340 displays a
high avidity towards properdin [54]. The binding strength is
important for later in vivo potency as well as future doses and
dosing intervals.
MAb 1340 interacts with native human properdin
multimers
MAbs are also characterized by a unique specificity, which was
tested by ELISA for anti-properdin mAbs. MAb 1340 and
commercial A235 specifically recognized human purified proper-
din or properdin in human serum (Figure 2A). Therefore, mAb
A235 was used as a control antibody in all further experiments.
Heat denatured or reduced properdin was not detected using mAb
1340 (data not shown). The novel mAb did not react with
unspecific proteins like mouse properdin, supernatant derived
from human embryonic kidney cells or fetal calf serum
(Figure 2A). In contrast, a widely used commercial mAb A233
detected all immobilized antigens and did not discriminate
between human, mouse and fetal calf properdin as well as cell
supernatant without properdin above 1 mg/mL but not at lower
concentrations. A233 cross-reactivity could be due to an enhanced
non-specific attraction between proteins and not necessarily to
antigen-antibody binding.
These results indicated a high specificity of mAb 1340 for
properdin and initiated a deeper characterization of the mAb 1340
interaction partners.
Properdin interacts in a multimeric structure with several other
human serum components. We used mAb 1340 to immunopre-
cipitate properdin multimers and associated proteins from serum
samples. The antibody detected different aggregated properdin
oligomers in a Western blot analysis (Figure 2B). The ratio of the
densitometric intensity of properdin trimer (165 kDa): dimer
(110 kDa): monomer (55 kDa) was 7:1:18. This ratio differed from
the previously described properdin oligomer ratio in blood [15]
and maybe due to a non-natural heat treatment-dependent
oligomer-aggregation during SDS-PAGE [55].
Native properdin multimers bind the C3-convertases of
complement [7]. Using mAb 1340 as a matrix we identified
components of a mAb 1340-immunoprecipitated protein mixture
at different sizes by mass spectrometry (Figure 3A). Properdin was
identified at a 55 kDa band. An exemplary mass spectrum for
amino acids 409–422 of properdin showed characteristic fragment
ions (Figure 3B). Additionally, C3(H2O) (.170 kDa) and C3
fragments (170 kDa, 68 kDa) were identified. Furthermore,
Figure 1. Anti-properdin antibodies show high avidity towards
human properdin. The binding strengths of newly generated mAb
1340 as well as commercially available mAb A233 and mAb A235 were
tested in an indirect ELISA. MAbs were serially diluted (1,000–0.1 ng/
mL) and properdin binding was detected with a peroxidase conjugated
anti-mouse IgG antibody. MAb 1340 (EC50 25 ng/mL), mAb A233 (EC50
11 ng/mL) and mAb A235 (EC50 15 ng/mL) showed comparable
binding strengths towards immobilized human properdin. Shown are
means (n = 96s.e.m.) out of three independent experiments each with
three replicates. After background subtraction, data were normalized to
1,000 ng/mL mAb 1340 reactivity against properdin (set to 100%).
doi:10.1371/journal.pone.0096371.g001
Antibody Inhibits Alternative Complement System and Detects Properdin
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e96371
clusterin (53 kDa) and human immunoglobulins (150 kDa) were
discovered as binding partners of properdin immobilized on mAb
1340 (Figure 3A). Factor Bb, the interaction partner of C3b in the
C3-convertase, was not detected. With the use of mAb 1340, we
identified novel interaction partners like IgG and clusterin that
seemed to include in a multimeric properdin protein complex in
soluble human serum.
The identified properdin interaction partners did not bind the
properdin epitope of mAb 1340, which was a discontinuous amino
acid sequence in the tertiary structure of properdin (Figure S1).
Three docking algorithms predicted different TSR subunits of a
properdin monomer for interaction with mAb 1340 in silico.
Properdin monomers form multimeric structures with connecting
loops, consisting of four TSRs [16]. The putative epitope of mAb
1340 could be located in this crucial interaction point of properdin
monomers, which resulted in different docking predictions to the
monomer (Figure S1D). Binding of mAb 1340 to single TSR
subunits showed no result in Western blot analysis or competitive
ELISA (Figure S2). The only binding partner for mAb 1340 was
a structural epitope of full length human properdin.
MAb 1340 inhibits properdin function
Alorco et al. described the properdin monomer connecting
vertexes as stabilization partners for the C3-convertase [16].
Binding of mAb 1340 to properdin showed an inhibition of the
C3-convertase in functional complement assays (Figure 4).
Human serum either preincubated with mAb 1340 or mAb
A235 resulted from 1–10 mg/mL mAb in a reduced lysis of sheep
red blood cells or E. coli cells, respectively (Figure 4A, B). Activity
of mAb 1340 and mAb A235 resulted in a blocking peak at 1.3–
2.7 mg/mL. At higher mAb concentrations cell lysis increased
again likely due to complement reactivation via immune complex
formation [56]. MAb 1340 and mAb A233 inhibited the binding
of properdin to immobilized C3b and as a consequence thereof
factor B binding was also diminished. MAb 235 did not interfere
with properdin deposition on C3b coated plates but inhibited
factor B binding to C3b (Figure S3).
The properdin targeting mAb 1340 and mAb A235 suppressed
the alternative complement system more effectively, than anti-C5
or anti-Ba antibodies (Figure 4A, B). Five to fifteen times more
antibody of C5 or Ba targeting mAbs were used to observe a
comparable maximum inhibition of the lytic effect of human
serum. An unspecific isotype control against botulinum toxin did
not inactivate the complement pathways.
The function of properdin in vivo offers an opportunity for a
selective manipulation of the alternative complement pathway. We
tested the inhibition of classical and alternative pathway mediated
by different mAb (Figure 4C). The alternative pathway was
influenced by anti-properdin mAb and anti-C5 mAb and the
classical complement system was only blocked by anti-C5 mAb.
These results demonstrated that mAb 1340 inhibited the activity of
properdin exclusively in the alternative complement pathway.
Detailed structure of mAb 1340 as a basis for
humanization
MAb 1340 is a highly affine, specific and blocking antibody
against properdin, with a mouse IgG 1 isotype and a k-light chain.
The immunoglobulin consisted of a highly glycosylated 35 kDa
light chain and a 55 kDa heavy chain in SDS-PAGE (data not
shown). Additionally, the amino acid sequence of the variable
domain of light and heavy chain showed a very low humanness
with a Z-score of 21.6 and 21.8, respectively. These structural
properties suggested a prospective humanization or chimerization
for an application in vivo. Therefore, the sequences of the
hypervariable loops of the antigen binding region were analyzed.
Seven different algorithms were used to predict the CDR
(Table 1). All programs identified regions within the variable
domains with overlapping amino acids (bold, underlined in
Table 1). CDR-H2, CDR-H3 and CDR-L3 showed the highest
consistency. Based on the amino acid sequence of the variable
Figure 2. Monoclonal antibodies specifically detect properdin in human serum. (A) Purified human properdin, human serum, recombinant
mouse properdin, human embryonic kidney (HEK) cell supernatant and fetal calf serum were immobilized on an ELISA plate. In house mAb 1340
(1 mg/mL) and commercial mAb A235 (1 mg/mL) detected only purified human properdin or human serum, respectively. MAb A233 (1 mg/mL)
detected all antigens tested. Shown are the respective means (6 s.e.m.) for two independent experiments. After background subtraction data were
normalized to mAb 1340 reactivity against properdin (set to 100%). (B) Human properdin was isolated from human serum by immunoprecipitation
(IP) using mAb 1340 (left lane). The precipitated proteins and purified control properdin (right lane) were separated by non-reducing, denatured SDS-
PAGE. Western blot detection was performed with mAb 1340 and a peroxidase conjugated anti-mouse IgG antibody. The generated mAb
precipitated and detected properdin monomer (,55 kDa), dimer (,110 kDa) and trimer (,165 kDa), respectively.
doi:10.1371/journal.pone.0096371.g002
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domains a three-dimensional model of mAb 1340 Fab was
generated (Figure 5A). The framework was built from b-sheets
and the CDRs formed a-helices. Predicted CDRs (bold, under-
lined in Table 1) formed an antigen binding cleft of 11.66–
24.64 A˚. The antibody binding groove was surrounded by amino
acids residuals, which were predicted as contact amino acids with
Figure 3. MAb 1340 precipitates properdin, complement factor 3, clusterin and immunoglobulins from human serum. (A) Proteins
from human serum binding to mAb 1340 were isolated by coimmunoprecipitation. After size separation in an SDS-PAGE, protein fractions were
identified using Coomassie staining and combined LC-MS/MS analysis. MAb 1340 precipitates complement factor C3(H2O) (.170 kDa) as well as C3-
fragments (,170 kDa), clusterin (53 kDa), immunoglobulins (150 kDa, murine IgG (mIgG), human IgG (hIgG)) and properdin (55 kDa). C3 fragments
detected at different molecular sizes, included: C3 b chain, C3c alpha chain fragments 1 and 2, C3dg at .170 kDa; C3 b chain, C3c alpha chain
fragments 1, C3dg at ,170 kDa and C3 b chain at 68 kDa. The confidence index for each identified protein is given by the molecular weight search
(MOWSE) score. (B) Exemplary MS/MS-spectrum matching the properdin peptide YPPTVSMVEGQGEK (amino acids 409–422) is shown. Detected C-
terminal ions (y-ions) are annotated within the peptide sequence.
doi:10.1371/journal.pone.0096371.g003
Figure 4. MAb 1340 inhibits function of the alternative complement system. (A) Effect of mAb 1340 on the alternative complement system
was tested in a hemolysis assay. Human normal serum was preincubated with different antibodies (0.03–50 mg/mL). Lysis of sheep erythrocytes was
measured at 414 nm after addition of the serum-mAb mixtures. Lysis of the erythrocytes was reduced after adding increasing concentrations of mAb
anti-properdin (mAb 1340 (blue), mAb A235 (green)). Other complement system specific antibodies resulted in an inhibition of the complement
system at higher concentrations (mAb anti-Ba (grey), mAb anti-C5 (red)). We observed lysis of sheep erythrocytes after incubation with a non-specific
mAb anti-botulinum neurotoxin (BoNT, orange, isotype control). (B) Inhibition of NHS-associated E. coli lysis by mAb was tested. E. coli were
cultivated in media with EGTA containing NHS and mAb in different concentrations (0.1–33 mg/mL). Percentages of viable E. coli cells were calculated
in comparison to an untreated control. The E. coli lysis assay showed comparable inhibitory results with the hemolysis assay. MAb A235 showed a
decrease in viable E. coli at concentrations above 1 mg/mL. (C) Blocking activity of different anti-complement mAb (6.6 mg/mL, anti-BoNT as isotype
control) for EGTA containing NHS (AP alternative pathway, black columns) and NHS (CP classical pathway, white columns) mediated lysis of E. coli was
analyzed. Anti-properdin mAb (mAb 1340, mAb A235) inhibited the alternative pathway but not the classical pathway. MAb anti-C5 blocked the lysis
of E. coli mediated by alternative and classical pathway. For all figures means out of two independent experiments (n = 46s.e.m., except for 4B
concentrations 0.08, 0.52, 2.6, 12.1 mg/mL n = 26s.e.m.) are shown.
doi:10.1371/journal.pone.0096371.g004
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the antigen (Figure 5B). The defined analyses of mAb 1340
structure provided valuable information for further antibody
modulations.
MAb 1340 detects specifically and reproducibly
properdin from human blood in a sandwich ELISA
To determine the properdin concentration in different patient
cohorts a sandwich-ELISA based on mAb 1340 was developed
and validated for human blood samples (Figure 6). Properdin
detection from human plasma was more sensitive than from
human serum with EC50 values of 30 ng/mL (1:800) and 50 ng/
mL (1:400), respectively. The linear range of the plasma standard
curve covered dilutions from 1:200 to 1:2,000 and the serum
standard curve showed a linear range from 1:100 to 1:1,000
(Figure 6A). Recovery rate of 100 ng/mL properdin spiked into
properdin depleted human plasma or serum differed over the
tested sample dilution range. Acceptable recovery rates between
80–125% were obtained for all tested plasma concentrations
(Figure 6B). Plasma did not alter the detection of spiked
properdin. In contrast, serum had to be diluted at least 1:50 to
avoid a masking matrix effect (Figure 6B) [57]. We tested the
specificity of the ELISA for different animal sera and only human
properdin was detected. There were no false positive results for
mouse, rat or bovine properdin (Figure 6C). Additionally, the
assay showed a high reproducibility for plasma dilutions less than
1:10,000 with a CV below 25% (Figure 6D). For serum samples a
difference in within-plate and plate-to-plate consistency was
determined. The intra-assay reproducibility (CV,25% at
1:10,000) for serum was better than the inter-assay reproducibility
(CV,25% at 1:1,000) (Figure 6D). The analyses of serum and
plasma samples within the linear range of the assay were
reproducible. We chose a dilution of 1:700 for all unknown
plasma and serum samples. This dilution is in the linear range of
the assay, gives acceptable recovery and sufficient reproducibility.
Properdin concentrations in patients with age-related
macular degeneration or rheumatic diseases and control
sera are similar
Complement activation is involved in AMD and different
rheumatoid diseases [58]. The properdin amount of AMD patients
(n = 20, mean 98% of positive control) corresponded to the
concentration in the healthy control group (n = 26, mean 102% of
the positive control) (Figure 7). There was also no significant
difference in the ELISA signal for properdin detection in the group
of rheumatoid diseases versus the control cohort (Figure 7).
Patients with connective tissue diseases (CTD, n = 10), polymyal-
gia rheumatica (PR, n = 31), rheumatoid arthritis (RA, n = 38),
spondyloarthritis (SPA, n = 40) and systemic sclerosis (SSc, n = 16)
showed no discriminable properdin detection compared to the
positive control (means were 94%, 99%, 95%, 103% and 100%,
respectively). Patients with systemic lupus erythematosus (SLE,
n = 6) showed a lower but not significant signal with 82% of the
control (two-tailed, paired t-test, P = 0.2496). These results
indicate a consistent systemic properdin serum concentration for
the analyzed diseases.
Discussion
MAb 1340 as a future complement therapeutic?
Complement protein deficiency or partial dysfunction can lead
to a disturbed homeostasis of the alternative pathway and as a
consequence result in pathological inflammatory processes.
Diseases such as AMD, rheumatic diseases and aHUS have been
associated with uncontrolled alternative complement activation
[58]. Different therapeutic interventions are under development to
specifically target the alternative pathway although this may be a
challenging task at hand [33]. There is a difficult balancing act to
inhibit the alternative complement pathway and at the same time
maintain the physiological function of this important player of the
innate immune system.
Figure 5. Structure of mAb 1340. (A) A model of mAb 1340 secondary structure shows the heavy (blue) and light (red) variable chain. The binding
cleft is determined by six CDR loops (marked are overlapping amino acids from Table 1) either in the heavy chain H1 (orchid), H2 (salmon), H3
(magenta) or in the light chain L1 (dark green), L2 (chartreuse), L3 (springgreen). The distance between the chains varies between 11.66–24.64 A˚.
Modeling was performed with Rosetta. (B) Spherical display of mAb 1340 light (light grey) and heavy (dark grey) variable chain. The predicted amino
acids for antigen contact are highlighted. The coloring of the residues is according to their contact probability value (the higher the probability the
deeper the color). Modeling was performed with proABC.
doi:10.1371/journal.pone.0096371.g005
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Therapeutic compounds like Eculizumab (anti-C5 mAb) or
Compstatin (anti-C3 peptide) target the central serine-proteases of
all three complement pathways and are tested in clinical studies for
aHUS as well as AMD, respectively [59,60]. Developments like
CFH supplements or anti-properdin antibodies offer the oppor-
tunity to influence regulators of the alternative complement
system, while the proteases are only indirectly blocked [61,62].
Beneficial effects of properdin inhibition in mouse models for
complement-mediated tissue injuries like arthritis or abdominal
aortic aneurysm have been shown [26–29,63]. The novel mAb
1340 described here is a mouse antibody with high affinity and
inhibiting activity against human native properdin. The inhibitory
efficiency of mAb 1340 is comparable to previously described anti-
human properdin immunoglobulins [37,64]. Complement-target-
ing antibodies with a specificity for C5 and factor B required
higher immunoglobulin concentrations to block the complement
pathway [65,66]. Given that the concentration of properdin in
human serum is 4–25 mg/mL, these data suggested that a dose of
3–13 mg/mL of mAb 1340 would be sufficient to block alternative
complement activation in a systemic application [11]. This is in
the range of established bioavailability of approved therapeutics
(Adalimumab 3.1–6.3 mg/mL, Alemtuzumab 2.5–6.1 mg/mL)
[67,68].
Bansal-Gupta et al. described a properdin targeting mAb, which
also showed blocking activity [37]. This antibody inhibited the
binding of C3 to properdin and interfered with C3-convertases of
all three complement pathways. Importantly, the reported mAb
1340 inhibits exclusively the alternative pathway by influencing
the interaction of C3 with properdin. MAb 1340 precipitated
properdin in association with high amounts of C3(H2O), human
IgG1 and clusterin from human serum. These results suggest that
properdin circulates in a protein complex in human blood and is
acting in concert with C3(H2O) or C3b as an initiator of
complement activation [44,69]. Previous studies have demonstrat-
ed that properdin binds Ba, the N-terminal part of factor B and
the von Willebrand factor type-A domain of the c-terminal
cleavage product Bb [16,17]. We have not observed factor B
fragments in coimmunoprecipitation and combined mass spec-
trometry analysis. The exact epitope of mAb 1340 is so far
unknown. We hypothesize that mAb 1340 binds to the vertexes of
properdin oligomers and inhibits binding of C3b and Factor B.
The activation of the C3-convertase can further be influenced
by unknown protective mechanisms which inhibit properdin-
C3(H2O)/C3b binding to cell surfaces [10]. An inhibitory effect
could be provided by clusterin, which was also identified in our
study from serum in combination with mAb 1340-properdin-
C3(H2O)/C3b. Clusterin suppresses cytolytic activity of terminal
components of the complement pathway C5b–7 [70]. While under
oxidative stress or accumulation of non-native deposits, clusterin
binds to stress epitopes and prevents proteins from aggregation
[71,72]. After clusterin dissociates from the C3b-properdin or
C5b–7, the complexes can bind to surfaces.
Previously established properdin blocking mAbs tested in our
study were commercially available mouse antibodies, but nothing
is known about the amino acid sequences or the structure of the
antigen-binding sites. However, this knowledge is crucial for future
application in humans. Therapeutic antibodies in clinical studies
are mainly humanized or chimeric antibodies [73]. MAb 1340 is
an antibody with a low humanness score, that could elicit a human
anti-mouse antibody response, fix complement at the Fc-region
and therefore result in a systemic inflammatory response [74].
Cloning of mAb 1340 CDRs into a human immunoglobulin
framework is required and would result in reduced immunoge-
nicity. The described three-dimensional model and detailed CDR
analysis of mAb 1340 helps to preserve the antibody specificity of
mAb 1340 for human oligomeric properdin after CDR-grafting,
back mutations and affinity maturation, required for future
therapeutic applications [75]. MAb 1340 allows for a pathway
specific inhibition and has a high potential for amelioration of
inflammation in vivo.
Table 1. Single letter amino acid sequence of complementarity-determining regions (CDR) of mAb 1340.
Algorithm/CDR H1 H2 H3
Kabat SGYWN IGYSGSTFYNPSLKR GDDLFPY
Chothia GDSITSG GYSGS GDDLFPY
IMGT GDSITSGYWN GYSGSTF TRGDDLFPY
AbM GDSITSGYWN FIGYSGSTF GDDLFPY
Contact SGYWN YMGFIGYSGSTF TRGDDLFP
V-BASE GDSITSGY IGYSGST TRGDDLFPY
Rosetta GDSITSGYWN FIGYSGSTFYNPSLKR GDDLFPY
Algorithm/CDR L1 L2 L3
Kabat RASQNISDYLQ YASQSIS QNGHSFPYT
Chothia RASQNISDYLQ YASQSIS QNGHSFPYT
IMGT QNISDY YAS QNGHSFPYT
AbM RASQNISDYLQ YASQSIS QNGHSFPYT
Contact SDYLQWY LLIKYASQSI QNGHSFPY
V-BASE QNISDY YAS QNGHSFPYT
Rosetta RASQNISDYLQ YASQSIS QNGHSFPYT
H variable domain of heavy chain, L variable domain of light chain; Kabat, Cothia, IMGT, AbM, Contact, VBASE2 and Rosetta are different CDR prediction algorithms; bold
and underlined marked amino acids are similar in all sequence.
doi:10.1371/journal.pone.0096371.t001
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Determination of stable systemic properdin
concentrations
The complement system and complement diagnostics were
described more than a century ago. However, complement
analysis in the clinic is limited to C3, C4, C1-inhibitor and overall
complement activity in hemolytic assays [76]. Detection of
properdin deficiency is a challenge as alternative pathway
hemolytic activity is low but often within the normal range [77].
The techniques improved in last years, but still lack standardiza-
tion, feasibility for multiparameter and bulk analyses [76,78].
Properdin diagnostics are done by radial immunodiffusion,
complement fixation assay or ELISA [32,34,57,79]. A described
sandwich ELISA used polyclonal antibodies and detected proper-
din from serum samples [57]. This ELISA showed similar recovery
rates and day-to-day variance as the reported ELISA with mAb
1340. Hoffmann et al. described a high dose hook effect in the
ELISA [57]. Our ELISA showed a dose-dependent slope of the
standard curve for serum and plasma without any inhibited
properdin detection at higher blood concentrations. The novel
properdin sandwich ELISA-based detection technique offers an
opportunity for a precise, reproducible and routine measurement
of properdin concentration in serum and plasma samples.
To our knowledge there is no standardized screening in
complement diagnostics for properdin deficiency or altered blood
titers in diseases so far. Therefore, effects of properdin deficiency
could easily be underdiagnosed. Properdin deficiencies are
orphan diseases, which are associated with increased susceptibil-
ity to meningococcal disease [80]. There is also evidence that
systemic and local properdin concentrations are modified in
certain immune-mediated disorders. Systemically decreased
properdin concentrations were reported for autoantibody-associ-
ated diseases like neuromyelitis optica, Scho¨nlein-Henoch syn-
drome and SLE [32–34]. Although not significant with the
present sample size of patients, we reproduced a reduction in
systemic properdin amounts in SLE patients’s serum. For other
rheumatic diseases and AMD a correlation with complement
activation was described [81,82]. However, we could not find any
systemic changes in the properdin concentrations in patients with
AMD, connective tissue diseases, polymyalgia rheumatica and
spondyloarthritis. Concordant with existing studies, we also did
Figure 6. A sandwich ELISA detected human properdin from blood samples highly sensitively, specifically and reproducibly. (A)
Serial dilutions of human normal plasma and serum pools (1:10–1:156,250) were used as a reference curve for properdin detection from human
samples in a sandwich ELISA. Detection of unknown samples was reliable in a plasma and serum dilution range from 1:100 to 1:1,000. The EC50 of the
plasma curve was at 1:800 and for serum at 1:400, respectively. The mean value of three independent measurements with duplicates is shown. The
reference curves were representable for all performed experiments. (B) Recovery rates of 100 ng/mL properdin from properdin-depleted NHP and
NHS are shown. Plasma matrix did not interfere with properdin recovery. Serum dilution 1:50 and higher gives a recovery rate between 75–125%. (C)
The described sandwich ELISA specifically detected human properdin only either purified or from blood samples. Properdin from mouse, rat or calf
serum showed no signal in an ELISA with immobilized antigens. Other negative controls such as human blood depleted from properdin, human
normal urine or bovine serum albumin were not detected. Two independent experiments with duplicates were performed. (D) Intra-assay and inter-
assay coefficient of variation for different plasma and serum concentrations in the sandwich ELISA displayed high reproducibility. Serial dilutions of a
human normal plasma and serum pool (1:10–1:156,250) were determined. The sandwich ELISA shows CV values below 25% for plasma dilutions from
1:10 to 1:10,000 and for serum dilutions 1:10 to 1:1,000, respectively.
doi:10.1371/journal.pone.0096371.g006
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not observe any significant deviation of serum titers for
autoantibody-associated diseases like rheumatoid arthritis or
systemic sclerosis [31,83]. Prompted by previous reports about
properdin reduction in synovial fluid in rheumatoid arthritis and
local properdin depletion in AMD affected eyes, we suggest a
local but not systemic change of properdin concentrations for
AMD and rheumatoid arthritis [31,84]. Animal experiments
showed local properdin-dependent cell-lysis can be caused by
systemically circulating properdin [28]. Thus, therapeutically
targeting systemic properdin and therefore ameliorating the
alternative complement system with mAb 1340 could be effective
and feasible in locally complement-mediated diseases like arthritis
or abdominal aortic aneurysm [25].
Conclusions
The recent success of complement inhibitors and reports about
properdin-associated diseases, illustrate a promising potential for
anti-properdin treatment in complement-mediated tissue injuries.
We anticipate that the development of the novel distinct properdin
inhibiting mAb 1340 and our specific properdin detection system
will be instrumental to further characterization of properdin and
its impact on human pathologies.
Supporting Information
Figure S1 MAb 1340 interacts with different thrombos-
pondin like repeats of properdin. Properdin is a 55 kDa
protein and consists of seven thrombospondin like repeats (TSR 0
yellow, TSR 1 purple, TSR 2 red, TSR 3 grey, TSR 4 green, TSR
5 blue, TSR 6 cyan). Each TSR is built of 49–84 amino acids with
connecting amino acids (yellow) between different TSRs. The
short C-terminus is depicted in grey. (A, B, C) In silico modeling of
docking showed binding of mAb 1340 heavy (blue) and light (red)
variable domain to different TSRs of a properdin monomer (PDB
1W0S, A chain). The different CDRs based on identical sequences
of Table 1 are shown. The large picture shows the interaction of
properdin and mAb 1340. The inlay enlarges the binding regions
between CDRs and TSR. (A) Prediction algorithm of PatchDock
showed an interaction of the CDRs H1, H2, L1 and L2 with TSR
1. (B) Binding of CDR H3, L1, L2 to TSR 3 and H2 to CDR 4
were described by the HexServer algorithm. (C) A third algorithm
docked CDR H2, L1 and L3 to TSR 4. Docking was performed
with GRAMM-X server. (D) A proposed model for a native
properdin multimer is shown [16]. Two properdin monomers
form a loop of four TSRs at each connecting point, respectively. In
this model mAb 1340 (grey circle) interacts with the connecting
points, based on the three in silico docking algorithms.
(TIF)
Figure S2 Determination of properdin thrombospondin
like repeat specificity of mAb 1340 shows only binding to
full length properdin. (A) Human properdin and TSR subunits
conjugated to maltose binding protein (MBP, 500 ng) were
separated on a 15% SDS-Gel and transferred on a PVDF
membrane. Protein detection was performed with mAb 1340. A
positive binding was reportable for full length human properdin
but not for the different TSR subunits. (B) A competitive ELISA
for mAb 1340 binding to human properdin or TSR was
performed. Different concentrations of mAb 1340 (0.06–
0.012 mg/mL, bars) were preincubated with different antigens in
solution (100 mg/mL, depicted on the x-axis). Antibody/antigen
mixtures were added to an ELISA plate, which was coated with
human properdin. MAb 1340 binding to immobilized properdin
was detected. Soluble human properdin inhibited the binding of
mAb 1340 to immobilized properdin. None of the TSRs did
inhibit the binding of different concentrations of mAb 1340 to
immobilized properdin. Shown is an example of two independent
experiments with similar results.
(TIF)
Figure 7. Systemic properdin concentrations in patient serum compared to healthy controls. Serum samples of healthy blood donors
(controls, n = 26), patients with age-related macular degeneration (AMD, n = 20), systemic lupus erythematosus (SLE, n = 6), connective tissue diseases
(CTD, n = 10), polymyalgia rheumatica (PR, n = 31), rheumatoid arthritis (RA, n = 38), spondyloarthritis (SPA, n = 40) and systemic sclerosis (SSc, n = 16)
were diluted in PBS (1:700). Properdin amount in serum samples was compared to a positive control (PC, NHS pool 1:700, ratio on y-axis) using the
described ELISA for human properdin (see Figure 6). Patient and control groups showed a properdin amount in serum between 66–155% of the
positive control. This corresponded to 13–30 mg/mL properdin. There was no significant difference in properdin concentration between the cohorts
(two-tailed, paired t-test, P.0.001).
doi:10.1371/journal.pone.0096371.g007
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Figure S3 MAb 1340 inhibits properdin and factor B
binding to C3b. The complement blocking activity of mAb 1340
(blue), mAb A233 (purple), mAb A235 (green) and mAb anti-
BoNT (orange) were tested on C3b coated plates. MAbs were
serially diluted (0.01–10 mg/mL) in (A) 10% or (B) 20% NHS/
MgEGTA buffer and incubated on a blocked C3b plate. (A)
Properdin deposition was detected with goat anti-properdin pAb
and (B) complement factor B (CFB) deposition was analyzed with
goat anti-CFB pAb. Signal was determined using a peroxidase
conjugated anti-goat antibody, TMB and measurement at
450 nm. All data were normalized to the NHS measurements
without mAb (set to 100%). Shown are means ((A) n = 66s.e.m.,
(B) n = 36s.e.m.) out of three independent experiments. MAb
1340 and mAb A233 blocked properdin and CFB deposition on
immobilized C3b. MAb A235 inhibited not properdin deposition
but CFB detection on C3b coated plates. The unspecific isotype
control did inhibit the complement activity.
(TIF)
Checklist S1 The ARRIVE Guidelines Checklist.
(DOCX)
Material and Methods S1 Competetive ELISA, Inhibition
of complement deposition, Software.
(DOCX)
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